The first generation of oral cephalosporin has good antibacterial effect on most strains of penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pneumoniae, group A hemolytic Streptococcus, etc. It also has certain antibacterial activity against Escherichia coli, Proteus mirabilis, Salmonella, Shigella, Haemophilus influenzae and gonococci. Methicillin-resistant Staphylococcus, Enterococcus, indole-positive Proteus, Enterobacter, Serratia and other Enterobacteriaceae, Pseudomonas aeruginosa and Bacteroides fragilis are resistant to this product.

This product belongs to the aminoglycoside antibiotics, and its antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on a variety of Gram-negative bacteria, and its antibacterial effect on Pseudomonas aeruginosa is 3 to 5 times stronger than that of gentamicin. Staphylococcus aureus is sensitive to this product, while streptococci, anaerobic bacteria, tuberculosis bacillus, rickettsia, viruses and fungi are resistant to this product. The mechanism of action is to inhibit the synthesis of bacterial proteins.

This product belongs to the macrolide antibiotics, which is the ethyl succinate of erythromycin. It is more stable than erythromycin in gastric acid. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can penetrate the bacterial cell membrane and form a reversible bond with the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

This product is an antifibrinolytic drug that can qualitatively inhibit the binding of plasminogen to fibrin, prevent its activation, and thus inhibit fibrinolysis; high concentrations (100 mg/L) directly inhibit the activity of plasmin and achieve a hemostatic effect.

This product is a synthetic antibacterial anti-tuberculosis drug. Its mechanism of action has not yet been fully elucidated. This product can penetrate into the mycobacteria to interfere with the synthesis of RNA, thereby inhibiting the reproduction of bacteria. This product is only effective against mycobacteria in the growth and reproduction period. So far, no cross-resistance has been found between this product and other anti-tuberculosis drugs.